On May 20, EDGC announced that it signed a strategic partnership with DxGen, which specializes in In-Vitro diagnostic medical devices and presenting EDGC RapidCheckTM COIVD-19 lgM/lgG.

This business agreement includes joint research and development of new IVD product, co-marketing for global market and commercialization of products by using diagnostic method that sequences virus samples.

The newly-developed Epithod 616 analyzer and COVID-19 IgM/IgG test kit from DxGen is the fastest system that not only provides positive (+, ++, +++) or negative (-) results, but also shows the results through a relative numerical value in COI (Cut-Off Index). Owing to its unique multi-chromatic reflectometry analyzer and flow-through immunoassay platform, the system can provide test results within two minutes, or more than 100 test results per hour, which significantly improves the total test capacity as compared to the conventional ‘Lateral-flow’ test kit that usually takes at least 10 minutes for each test.